[go: up one dir, main page]

HN2002000235A - Formulaciones en combinacion de derivados de 1, 4 - benzotiepina - 1, 1 - dioxido con otras sustancias activas, y su utilización - Google Patents

Formulaciones en combinacion de derivados de 1, 4 - benzotiepina - 1, 1 - dioxido con otras sustancias activas, y su utilización

Info

Publication number
HN2002000235A
HN2002000235A HN2002000235A HN2002000235A HN2002000235A HN 2002000235 A HN2002000235 A HN 2002000235A HN 2002000235 A HN2002000235 A HN 2002000235A HN 2002000235 A HN2002000235 A HN 2002000235A HN 2002000235 A HN2002000235 A HN 2002000235A
Authority
HN
Honduras
Prior art keywords
benzothypine
formulations
combination
active substances
dioxide
Prior art date
Application number
HN2002000235A
Other languages
English (en)
Inventor
Heiner Glombik
Wendelin Frick
Hans Ludwing Schaefer
Werner Kramer
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10140169A external-priority patent/DE10140169A1/de
Priority claimed from DE10142456A external-priority patent/DE10142456A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of HN2002000235A publication Critical patent/HN2002000235A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)

Abstract

LA PRESENTE INVENCIÓN SE BASO EN LA MISION DE PONER A DISPOSICIÓN MEZCLAS DE SUSTANCIAS O FORMULACIONES EN COMBINACION DE DERIVADOS DE 1,4 BENZOTIEPINA - 1, 1 - DIOXIDO DE LA FORMULA 1 CON OTRAS SUSTANCIAS ACTIVAS, QUE DESARROLLEN UN EFECTO SINERGICO.
HN2002000235A 2001-08-22 2002-08-20 Formulaciones en combinacion de derivados de 1, 4 - benzotiepina - 1, 1 - dioxido con otras sustancias activas, y su utilización HN2002000235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10140169A DE10140169A1 (de) 2001-08-22 2001-08-22 Kombinationspräparate von 1,4-Benzothiepin-1,1-dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung
DE10142456A DE10142456A1 (de) 2001-08-31 2001-08-31 Kombinationspräparate von 1,4-Benzothiepin-1,1dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung

Publications (1)

Publication Number Publication Date
HN2002000235A true HN2002000235A (es) 2003-02-18

Family

ID=26009944

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2002000235A HN2002000235A (es) 2001-08-22 2002-08-20 Formulaciones en combinacion de derivados de 1, 4 - benzotiepina - 1, 1 - dioxido con otras sustancias activas, y su utilización

Country Status (29)

Country Link
US (2) US20030158119A1 (es)
EP (1) EP1425018B1 (es)
JP (1) JP2005501861A (es)
KR (1) KR20040032937A (es)
CN (1) CN1655792A (es)
AR (1) AR035285A1 (es)
AT (1) ATE411802T1 (es)
AU (1) AU2002333373B2 (es)
BR (1) BR0212031A (es)
CA (1) CA2457976A1 (es)
CO (1) CO5560550A2 (es)
DE (1) DE50212937D1 (es)
HN (1) HN2002000235A (es)
HR (1) HRP20040171A2 (es)
HU (1) HUP0401318A3 (es)
IL (1) IL160474A0 (es)
MA (1) MA26317A1 (es)
MX (1) MXPA04001328A (es)
NO (1) NO20040702L (es)
NZ (1) NZ531293A (es)
OA (1) OA12654A (es)
PA (1) PA8553201A1 (es)
PE (1) PE20030361A1 (es)
PL (1) PL366851A1 (es)
RS (1) RS11104A (es)
RU (1) RU2297222C2 (es)
TN (1) TNSN04034A1 (es)
UY (1) UY27419A1 (es)
WO (1) WO2003018024A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE102006053637B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053635B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE502007006208D1 (de) 2006-11-14 2011-02-17 Sanofi Aventis Deutschland Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2765855A4 (en) 2011-10-12 2015-03-25 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FOR DISPERSION INHIBITION
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
AU2012328453B2 (en) 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
BR112015023646A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
BR112021015799A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) * 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
EA200100704A1 (ru) * 1998-12-23 2002-02-28 Джи.Ди.Сирл Ллс Комбинация для применения по сердечно-сосудистым показаниям
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
ATE245636T1 (de) 1999-07-29 2003-08-15 Lilly Co Eli Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
KR20020033778A (ko) * 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
PT1277736E (pt) * 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use

Also Published As

Publication number Publication date
OA12654A (en) 2006-06-15
ATE411802T1 (de) 2008-11-15
HRP20040171A2 (en) 2004-10-31
AU2002333373B2 (en) 2006-12-14
NZ531293A (en) 2005-08-26
WO2003018024A1 (de) 2003-03-06
DE50212937D1 (de) 2008-12-04
UY27419A1 (es) 2003-04-30
RU2004108119A (ru) 2005-04-10
HUP0401318A3 (en) 2008-03-28
RU2297222C2 (ru) 2007-04-20
AR035285A1 (es) 2004-05-05
PE20030361A1 (es) 2003-05-27
EP1425018B1 (de) 2008-10-22
PA8553201A1 (es) 2004-08-31
US7179792B2 (en) 2007-02-20
US20040097424A1 (en) 2004-05-20
KR20040032937A (ko) 2004-04-17
IL160474A0 (en) 2004-07-25
EP1425018A1 (de) 2004-06-09
TNSN04034A1 (en) 2006-06-01
MXPA04001328A (es) 2004-05-05
JP2005501861A (ja) 2005-01-20
HUP0401318A2 (hu) 2004-10-28
CO5560550A2 (es) 2005-09-30
NO20040702L (no) 2004-05-19
RS11104A (sr) 2006-12-15
PL366851A1 (en) 2005-02-07
US20030158119A1 (en) 2003-08-21
MA26317A1 (fr) 2004-10-01
CN1655792A (zh) 2005-08-17
BR0212031A (pt) 2004-08-03
CA2457976A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
HN2002000235A (es) Formulaciones en combinacion de derivados de 1, 4 - benzotiepina - 1, 1 - dioxido con otras sustancias activas, y su utilización
DE69907977D1 (de) Pyrrolobenzodiazepine
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
DE60120160D1 (de) Kleidungstück
TR200201887T2 (tr) Sulu elastomer kaplama bileşimi ve bununla kaplanmış cisimler.
BR0006005A (pt) Composição estável de óleo em glicerinatopicamente aplicável
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2165523T3 (es) Derivados de la ciclopentano-1,3-diona.
GT200200200A (es) Productos para la axila, con componente de bloqueo de agua
ES2092874T3 (es) Composicion de organopolisiloxano de aspecto gelificado, sin gelificante, utilizable en cosmetica y dermatologia.
ES2189657B1 (es) Composiciones de resina plaguicidas.
ECSP034558A (es) Moduladores del receptor estrogeno
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
DE60116359D1 (de) Kahalalid f formulierung
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
AR046120A1 (es) Fomulaciones fungicidas que contienen cobre
BR0213536A (pt) Formulações de xarope de ribavirina
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
BR0114431A (pt) Composição pesticida
ATE305517T1 (de) Neurotrypsin
BR0114065A (pt) Triazolo-epotilonas
SV2004001441A (es) Compuestos de isocromano ref. x-14205